Core Viewpoint - Advanced Micro Devices, Inc. (NASDAQ:AMD) is recognized as one of the top stocks to buy in 2026, with analysts maintaining a bullish outlook despite some concerns regarding the MI450-series chips [1][2]. Group 1: Analyst Ratings and Price Targets - UBS raised the price target for AMD from $300 to $330, citing strong demand for the MI450-series [1]. - Wells Fargo analyst Aaron Rakers reaffirmed an Overweight rating on AMD, maintaining a price target of $345, indicating confidence in the company's trajectory towards MI450-series ramp-up in the second half of 2026 [3]. - Among 58 analysts covering AMD, 79% rate the stock as a Buy, while 21% rate it as a Hold, with a median price target of $290.50, suggesting over 22% upside potential [4]. Group 2: Company Performance and Market Position - AMD shares have increased by over 100% over the past year, making it one of the most rewarding stocks during this period [4]. - The company is a leading semiconductor firm in the US, offering AI accelerators, x86 microprocessors, and GPUs, and operates in three segments: Data Center, Client and Gaming, and Embedded [5]. Group 3: Market Sentiment and Challenges - Despite the positive outlook from some analysts, reports from SemiAnalysis suggested that AMD's MI450-series chips are behind schedule, which led to a sell-off and a share price drop of over 6% on January 30 [2].

Core Viewpoint - Johnson & Johnson (NYSE: JNJ) has been upgraded by Morgan Stanley from Equal Weight to Overweight, with a new price target of $262, indicating a positive outlook for the company's future performance [1][2]. Group 1: Analyst Insights - Terence Flynn from Morgan Stanley anticipates higher earnings estimates for Johnson & Johnson due to new product cycles, projecting earnings to exceed consensus estimates by nearly 20% [2][3]. - Flynn highlighted that Johnson & Johnson has one of the most robust new product cycles in the biopharma industry, raising estimates for products such as Tremfya, Icotyde, Tecvayli, and Darzalex [3]. Group 2: Stock Performance and Analyst Ratings - Over the past year, Johnson & Johnson shares have returned over 48.50%, with 57% of analysts rating it a Buy, 36% a Hold, and 7% a Sell [4]. - The median price target among analysts is $240, suggesting an upside of just under 6%, while Morgan Stanley's target of $262 indicates a potential upside of 15.25% [4]. Group 3: Company Overview - Johnson & Johnson is involved in the research, development, manufacturing, and sale of a variety of healthcare products globally, operating through two segments: Innovative Medicine and MedTech [5].

Broadcom Inc. (NASDAQ:AVGO) is one of the 10 Hottest Stocks to Buy in 2026. On January 23, Cathie Wood made another purchase of Broadcom Inc. (NASDAQ: AVGO) shares, marking her fourth trade in the semiconductor firm this month. Through her Ark Innovation ETF (ARKK) and Ark Next Generation Internet ETF (ARKW), Wood added 49,048 shares of AVGO valued at $15.96 million on January 23. Cathie Wood Remains Bullish on Broadcom Amid AI and Datacenter Exposure Copyright: limonzest / 123RF Stock Photo Earlier, W ...

Core Insights - OSR Holdings, Inc. emphasizes its strong fundamentals and commitment to long-term value creation despite market volatility and uncertainty [2][7] - The company is making significant progress in licensing its lead asset, VXM01, through a binding term sheet with BCM Europe AG, which is seen as a validation of its biotech strategy [3][8] - Ongoing strategic discussions for a merger between its medical device subsidiaries, RMC and Woori IO, are encouraged by recent regulatory clarity from the U.S. FDA, enhancing commercialization strategies [4][5] Licensing and Development - The licensing transaction for VXM01 could yield up to USD 815 million in development, regulatory, and commercial milestones, with an upfront consideration of USD 30 million [8] - The transaction structure is progressing in line with previously disclosed economic frameworks, indicating a positive outlook for the asset [3] Medical Device Strategy - Woori IO is positioned to pursue a dual-track commercialization strategy for consumer wearable products, which can be marketed independently of medical-device regulatory approvals [9] - The merger with RMC is expected to create a strong foundation for growth, with plans for a potential listing on the KOSDAQ market, which has recently reached a 25-year high [6] Future Outlook - OSR Holdings is focused on disciplined capital allocation and strategic partnerships to enhance its portfolio of healthcare technologies, maintaining its mission despite short-term market dynamics [7][10] - The management is actively engaging with regulators and partners to meet Nasdaq listing requirements while advancing transactions that could unlock substantial shareholder value [10]

Company Overview - Bronco Resources Corp. is a mineral exploration company listed on the TSX Venture Exchange, focusing on the Placer Mountain Gold Project located in Princeton, BC, held in an 88%/12% joint venture with Universal Copper Ltd [5] Leadership Change - Dev Rishy-Maharaj has been appointed as the new Chief Executive Officer and Director of Bronco Resources, succeeding Corbin Stewart, who will remain as a Director [1][3] - Rishy-Maharaj brings 14 years of experience in mining and mineral exploration, with a background in operations across British Columbia, Yukon, and Ontario, including leadership roles in both greenfield and brownfield exploration projects [2] Strategic Focus - The company aims to leverage the current strong gold prices to enhance shareholder value, with a disciplined approach to capital deployment as it advances the Placer Mountain Gold Project [4] - Rishy-Maharaj expressed excitement about leading the company during a favorable market for gold, indicating a methodical exploration approach [3] Stock Options - Bronco Resources has granted a total of 825,000 stock options to directors, officers, and consultants at an exercise price of $0.06 for a period of five years, pending approval from the TSX Venture Exchange [4]

Gold and silver prices surged to new highs early in 2026 as investors looked for ways to hedge against stock market volatility and an uncertain geopolitical environment. The same dynamics might make coins a good investment as well. Are coins considered a safe-haven asset in 2026? Here’s what experts have to say. Also see the five most valuable American coins still in circulation. What the Past Tells Us If the past is any indication, this might be a good time to invest in collectible coins. When gold a ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted a ...

Eldorado Gold (TSX: ELD) (NYSE: EGO) has agreed to buy fellow Canadian miner Foran Mining (TSX:FOM) (OTCQX:FMCXF) in a transaction that values the copper-focused developer at about C$3.8 billion ($2.8 billion).The acquisition will expand Eldorado’s copper footprint while adding a second near-term growth project as demand for the metal rises alongside electrification and clean energy investment.The deal brings together Eldorado’s Skouries gold-copper project in Greece and Foran’s McIlvenna Bay copper project ...

Core Insights - Alan Brochstein has been a significant contributor to Seeking Alpha since 2007, focusing on the cannabis industry and ETFs [1] - He founded AB Analytical Services in 2007 to provide independent consulting to registered investment advisors [1] - Brochstein launched 420 Investor in 2013, a subscription service focused on cannabis stocks, and has been managing it on the Seeking Alpha platform [1] - He has been a proponent of ETFs for decades, emphasizing their role in enabling diversified investment portfolios at a reasonable cost [1] - Brochstein maintains a 79-ETF Focus List that includes both popular and lesser-known ETFs, and he created a model portfolio as of year-end 2025 [1] Company and Industry Focus - Brochstein was one of the first investment professionals to focus exclusively on the cannabis industry starting in 2014 [1] - New Cannabis Ventures, which Brochstein manages, has been a leading provider of financial information in the cannabis industry since 2015 [1] - The ETF universe has grown significantly, and Brochstein aims to help investors understand their holdings and the associated risks [1]

William Blair's senior analyst Louie DiPalma believes Palantir Technologies (NASDAQ: PLTR) will report a strong Q4, paving the way for the AI stock to surpass $200 again by the end of 2026. The data a... ...